RU2613555C2 - Моногидратный кристалл калиевой соли фимасартана, способ его получения и содержащая его фармакологическая композиция - Google Patents
Моногидратный кристалл калиевой соли фимасартана, способ его получения и содержащая его фармакологическая композиция Download PDFInfo
- Publication number
- RU2613555C2 RU2613555C2 RU2015117524A RU2015117524A RU2613555C2 RU 2613555 C2 RU2613555 C2 RU 2613555C2 RU 2015117524 A RU2015117524 A RU 2015117524A RU 2015117524 A RU2015117524 A RU 2015117524A RU 2613555 C2 RU2613555 C2 RU 2613555C2
- Authority
- RU
- Russia
- Prior art keywords
- potassium salt
- monohydrate
- carried out
- timasartan
- drying
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2012-0113848 | 2012-10-12 | ||
| KR20120113848A KR101490329B1 (ko) | 2012-10-12 | 2012-10-12 | 피마살탄 포타슘염의 일수화물 결정, 그 제조방법, 및 그를 포함하는 약제학적 조성물 |
| PCT/KR2013/009097 WO2014058268A1 (ko) | 2012-10-12 | 2013-10-11 | 피마살탄 포타슘염의 일수화물 결정, 그 제조방법, 및 그를 포함하는 약제학적 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2015117524A RU2015117524A (ru) | 2016-12-10 |
| RU2613555C2 true RU2613555C2 (ru) | 2017-03-17 |
Family
ID=50477658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015117524A RU2613555C2 (ru) | 2012-10-12 | 2013-10-11 | Моногидратный кристалл калиевой соли фимасартана, способ его получения и содержащая его фармакологическая композиция |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP2927226A4 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101490329B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN104854099B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2013330603B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015008170A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2887056C (cg-RX-API-DMAC7.html) |
| IN (1) | IN2015DN03975A (cg-RX-API-DMAC7.html) |
| MX (1) | MX353635B (cg-RX-API-DMAC7.html) |
| MY (1) | MY169064A (cg-RX-API-DMAC7.html) |
| PH (1) | PH12015500794A1 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2613555C2 (cg-RX-API-DMAC7.html) |
| SA (1) | SA515360275B1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014058268A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101545268B1 (ko) * | 2015-02-05 | 2015-08-20 | 보령제약 주식회사 | 정제 및 이의 제조방법 |
| CN105784867B (zh) * | 2016-03-28 | 2019-01-01 | 北京睿创康泰医药研究院有限公司 | 用于分析非马沙坦有关物质的hplc方法及这些杂质作参比标准的用途 |
| KR102247408B1 (ko) | 2017-09-18 | 2021-05-03 | 보령제약 주식회사 | 피마살탄 프로드러그 |
| KR102402501B1 (ko) * | 2018-04-24 | 2022-05-26 | (주)국전약품 | 피마살탄 트로메타민염 및 이를 포함하는 약제학적 조성물 |
| KR102221856B1 (ko) * | 2020-10-12 | 2021-03-02 | 유니셀랩 주식회사 | 신규한 피마살탄 결정형의 다형체 |
| KR20230062917A (ko) | 2021-11-01 | 2023-05-09 | 그린케미칼 주식회사 | 피마살탄 일수화물 b형 결정다형 및 그 제조방법 |
| KR20230062916A (ko) | 2021-11-01 | 2023-05-09 | 그린케미칼 주식회사 | 피마살탄 무수물 a형 결정다형 및 그 제조방법 |
| KR102968871B1 (ko) | 2023-03-30 | 2026-05-26 | (주) 에프엔지리서치 | 피마살탄의 신규 염 및 이의 제조방법 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010090193A (ko) * | 2000-03-23 | 2001-10-18 | 조생현 | 피리미디논 화합물 및 이의 염의 제조방법 |
| KR20040032639A (ko) * | 2002-10-10 | 2004-04-17 | 보령제약 주식회사 | 피리미디논 화합물 및 이의 염의 삼수화물의 제조 방법 |
| RU2233278C2 (ru) * | 1998-04-25 | 2004-07-27 | Бориюнг Фармасьютикал Ко., Лтд. | Пиримидиновые соединения, способ их получения и фармацевтическая композиция |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100300566B1 (ko) * | 1994-09-17 | 2001-11-22 | 조생현 | 피리미디논유도체와그의제조방법및용도 |
| CA2461060C (en) * | 2001-09-21 | 2010-07-27 | Boryung Pharmaceutical Co., Ltd. | Method for preparing pyrimidinone compound and pharmaceutically acceptable salts thereof |
| SG194162A1 (en) * | 2011-04-12 | 2013-11-29 | Boryung Pharm | Antihypertensive pharmaceutical composition |
-
2012
- 2012-10-12 KR KR20120113848A patent/KR101490329B1/ko not_active Expired - Fee Related
-
2013
- 2013-10-11 CN CN201380063465.5A patent/CN104854099B/zh not_active Expired - Fee Related
- 2013-10-11 IN IN3975DEN2015 patent/IN2015DN03975A/en unknown
- 2013-10-11 BR BR112015008170A patent/BR112015008170A2/pt not_active Application Discontinuation
- 2013-10-11 WO PCT/KR2013/009097 patent/WO2014058268A1/ko not_active Ceased
- 2013-10-11 RU RU2015117524A patent/RU2613555C2/ru active
- 2013-10-11 MX MX2015004573A patent/MX353635B/es active IP Right Grant
- 2013-10-11 EP EP13845572.0A patent/EP2927226A4/en not_active Withdrawn
- 2013-10-11 MY MYPI2015000875A patent/MY169064A/en unknown
- 2013-10-11 CA CA2887056A patent/CA2887056C/en not_active Expired - Fee Related
- 2013-10-11 AU AU2013330603A patent/AU2013330603B2/en not_active Ceased
-
2015
- 2015-04-10 PH PH12015500794A patent/PH12015500794A1/en unknown
- 2015-04-12 SA SA515360275A patent/SA515360275B1/ar unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2233278C2 (ru) * | 1998-04-25 | 2004-07-27 | Бориюнг Фармасьютикал Ко., Лтд. | Пиримидиновые соединения, способ их получения и фармацевтическая композиция |
| KR20010090193A (ko) * | 2000-03-23 | 2001-10-18 | 조생현 | 피리미디논 화합물 및 이의 염의 제조방법 |
| KR20040032639A (ko) * | 2002-10-10 | 2004-04-17 | 보령제약 주식회사 | 피리미디논 화합물 및 이의 염의 삼수화물의 제조 방법 |
Also Published As
| Publication number | Publication date |
|---|---|
| SA515360275B1 (ar) | 2017-07-11 |
| CA2887056A1 (en) | 2014-04-17 |
| AU2013330603A1 (en) | 2015-05-28 |
| CN104854099B (zh) | 2016-11-16 |
| PH12015500794A1 (en) | 2015-06-15 |
| MX2015004573A (es) | 2015-07-21 |
| BR112015008170A2 (pt) | 2017-07-04 |
| KR101490329B1 (ko) | 2015-02-04 |
| EP2927226A1 (en) | 2015-10-07 |
| RU2015117524A (ru) | 2016-12-10 |
| MY169064A (en) | 2019-02-12 |
| KR20140047483A (ko) | 2014-04-22 |
| AU2013330603B2 (en) | 2016-03-31 |
| WO2014058268A1 (ko) | 2014-04-17 |
| CN104854099A (zh) | 2015-08-19 |
| EP2927226A4 (en) | 2016-07-13 |
| MX353635B (es) | 2018-01-22 |
| CA2887056C (en) | 2017-09-05 |
| IN2015DN03975A (cg-RX-API-DMAC7.html) | 2015-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3969449B1 (en) | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer | |
| AU2013330603B2 (en) | Monohydrate crystal of fimasartan potassium salt, method for preparing same, and pharmacological composition comprising same | |
| CN104736526B (zh) | 沃替西汀盐及其晶体、它们的制备方法、药物组合物和用途 | |
| JP2026031970A (ja) | Glp-1受容体アゴニストの結晶形aおよびその調製法 | |
| EP3365321B1 (en) | Solabegron zwitterion and uses thereof | |
| EP3551617B1 (en) | Compositions and methods related to pyridinoylpiperidine 5-ht1f agonists | |
| WO2013189910A1 (en) | Multicomponent crystals comprising imatinib mesilate and selected co-crystal formers | |
| US9073899B2 (en) | Solid forms of dabigatran etexilate mesylate and processes for their preparation | |
| CN104284897B (zh) | 替卡格雷晶型及其制备方法和用途 | |
| JP7168447B2 (ja) | ビラスチンの結晶形態及びそれらの調製方法 | |
| CN111683934B (zh) | (r)-3-(1-(2,3-二氯-4-(吡嗪-2-基)苯基)-2,2,2-三氟乙基)-1-甲基-1-(1-甲基哌啶-4-基)脲的延胡索酸盐、制备方法及其用途 | |
| CN101993417A (zh) | 磷酸二甲啡烷的稳定新晶型 | |
| JP7457033B2 (ja) | アルドース還元酵素阻害剤の塩、及びその製造方法と使用 | |
| WO2015107545A1 (en) | Water soluble salts of dasatinib hydrate | |
| WO2015149270A1 (zh) | 曲格列汀半琥珀酸盐的晶体及其制备方法和药物组合物 | |
| EP2610239A1 (en) | Preparation Of Rasagiline Hemitartrate | |
| HK40079891A (en) | Compositions and methods related to pyridinoylpiperidine 5-ht1f agonists | |
| HK40127061A (en) | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer | |
| WO2023197934A1 (zh) | 阿片受体拮抗剂缀合物的固体盐型、晶型及其制备方法、组合物和用途 | |
| HK40079890A (en) | Compositions and methods related to picolinylpiperidine 5-ht1f agonists | |
| HK40092799A (en) | Polymorphs of a hydrochloride salt of pn6047 | |
| HK40065390A (en) | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer | |
| HK40065390B (en) | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer | |
| CN109796400A (zh) | 一种甲苯磺酸索拉菲尼晶型及其制备方法 | |
| JPWO2003008388A1 (ja) | N−{2−クロロ−4−[(6,7−ジメトキシ−4−キナゾリニル)オキシ]フェニル}−n’−プロピルウレアのi型結晶およびその製造法 |